Bristol-Myers Squibb Co.

NYSE:BMY   3:59:57 PM EDT
66.84
+0.37 (+0.56%)
4:00:00 PM EDT: $66.83 -0.01 (-0.02%)
Products

Bristol Myers & Acceleron Present First Results From Phase 2 Beyond Study Of Reblozyl

Published: 06/11/2021 07:28 GMT
Bristol-Myers Squibb Co. (BMY) - Bristol Myers Squibb and Acceleron Present First Results From Phase 2 Beyond Study of Reblozyl® (luspatercept-aamt) in Adults With Non-transfusion Dependent (ntd) Beta Thalassemia.
Results Showed Treatment With Reblozyl Plus Best Supportive Care Improved Anemia in 77% of Patients Compared to Placebo.
89.6% of Patients Treated With Reblozyl Remained Transfusion Free Versus.
67.3% of Patients in Placebo Arm at Weeks 1-24.
Bristol-myers Squibb - in Study, 89.6% of Patients Treated With Reblozyl Remained Transfusion Free Versus.
67.3% of Patients in Placebo Arm at Weeks 1-24.
Bristol-reblozyl Was Well Tolerated, Improvements in Hemoglobin Correlated With Improved Patient-reported Outcomes Over a Continuous 12-week Interval.